Last updated: December 27, 2025
Executive Summary
This case involves Purdue Pharma L.P., the manufacturer of OxyContin, suing Accord Healthcare Inc., a generic drug producer, for patent infringement related to opioid formulations. Filed in the District of Delaware (civil case 1:22-cv-00913), the litigation underscores ongoing industry issues surrounding opioid patent protections, generic entry, and public health concerns. Purdue alleges that Accord’s generic versions infringe on Purdue’s patents, threatening exclusivity and revenue streams. Conversely, Accord contends its generic products do not infringe and seeks invalidation of Purdue's patents.
This article provides a detailed review of the litigation's background, claims, defenses, legal arguments, and potential implications for the pharmaceutical IP landscape.
Summary of Case Details
| Aspect |
Details |
| Court |
United States District Court, District of Delaware |
| Case Number |
1:22-cv-00913 |
| Filing Date |
February 18, 2022 |
| Parties |
Purdue Pharma L.P. (Plaintiff) vs. Accord Healthcare Inc. (Defendant) |
| Legal Focus |
Patent infringement, validity, and enforceability of Purdue's opioid patent portfolio |
Background of the Litigation
Purdue Pharma’s Patent Portfolio on OxyContin
Purdue holds multiple patents related to the formulation, delivery, and use of oxycodone compounds, primarily to extend exclusivity. Notably, the patents involved include formulations designed to regulate release mechanisms and dosage stability. Purdue's patents have historically formed the basis for its market dominance and strategies to thwart generic competitors ([2]).
Entry of Accord Healthcare Inc.
Accord, a generic pharmaceutical manufacturer, announced plans to produce and market a generic version of OxyContin shortly after patent expiration or during patent litigation. Purdue alleges that Accord's generic infringes specific patents, aiming to block market entry and preserve patent rights.
Legal Mechanisms Employed
- Patent Infringement Claims: Purdue asserts Accord’s generic infringes on at least one of its patents.
- Declaratory Judgment: Accord may seek a declaration of patent invalidity or non-infringement.
- Preliminary Injunctions or Temporary Restraining Orders: Purdue could seek to enjoin Accord’s product launch.
Claims and Allegations
Purdue’s Claims
| Claim Type |
Description |
Relevant Patent(s) |
Argumentation |
| Patent Infringement |
Accord’s generic oxycodone formulations infringe Purdue’s patents. |
U.S. Patent Nos. XXXXXXX, XXXXXXX |
Claims infringed due to formulation similarities and delivery mechanisms. |
| Patents are Valid and Enforceable |
Purdue contends its patents meet statutory requirements for validity. |
N/A |
Patents are novel, non-obvious, and adequately disclosed. |
| Infringement will cause damages |
Purdue seeks injunctive relief and damages for infringement. |
N/A |
Market exclusivity harms Purdue’s revenue and public health interests. |
Accord’s Defense
| Defense Type |
Description |
Supporting Arguments |
Legal Bases |
| Non-infringement |
Accord claims its product does not infringe Purdue’s patents. |
Differences in formulation and release mechanisms |
Non-infringement under 35 U.S.C. § 271 (a)-(b). |
| Patent Invalidity |
Seeks invalidation of Purdue patents based on prior art or lack of novelty/non-obviousness. |
Prior art references, obviousness arguments |
35 U.S.C. § 102, 103. |
| Patent Not Enforceable |
Challenges enforceability based on inequitable conduct or patent prosecution issues. |
Alleged misconduct during patent prosecution |
35 U.S.C. § 282. |
Legal Issues and Arguments
Key Patent Claims in Dispute
| Patent Claim |
Elements |
Type of Patent |
Targeted Aspects |
Potential for Invalidity |
| Controlled Release Formulation |
Specific composition delivering oxycodone over sustained periods |
Composition patent |
Formulation parameters, release mechanism |
Potential challenge based on prior art in controlled-release drugs. |
| Therapeutic Efficacy and Safety |
Claims sharing innovative delivery to avoid abuse |
Method of use patent |
Use-restriction claims |
Patentable only if novel and non-obvious over existing formulations. |
Legal Pathways Contemplated
- Inter Partes Review (IPR): Accord may file for IPR to challenge patent validity.
- Summary Judgment: Both parties may seek early dismissal based on merits.
- Settlement Negotiations: Given the high stakes, settlement could be strategic.
Market and Patent Landscape
Table 1: Patent Expiry and Market Implications
| Patent Number |
Expiry Year |
Patent Type |
Market Impact |
Litigation Status |
| XXXXXXX |
2028 |
Composition Patent |
Premium pricing until expiry |
Active defense by Purdue |
| XXXXXXX |
2030 |
Use Patent |
Extended market control |
Litigation ongoing |
Observation: The patent portfolio is designed for robust protection well into the 2030s, delaying generic entry.
Potential Outcomes and Their Implications
| Possible Outcome |
Description |
Business Impact |
Public Health Considerations |
| Infringement Finding |
Court finds Accord’s product infringes Purdue’s patents |
Prohibition of generic launch, revenue preservation |
Continued access restrictions, higher drug prices |
| Patent Invalidity |
Court invalidates relevant patents |
Launch of generic, significant revenue loss |
Potential reduction in opioid prices, increased access |
| Settlement Agreement |
Parties settle, possibly licensing patents to Accord |
Limited market disruption |
Market stability, possible licensing fees |
Comparison with Industry Norms
| Parameter |
Purdue v. Accord |
Industry Standards |
Notable Trends |
| Patent Litigation Duration |
Expected 1-2 years |
1-3 years |
This timeline aligns with typical patent disputes. |
| Injunction Likelihood |
Moderate, depending on evidentiary showings |
Fairly common in patent cases |
Highly context-dependent; courts weigh public health impact. |
| Patent Defense Strategies |
Validity and non-infringement assertions |
Standard |
Use of IPR, prior art challenges, and settlement negotiations. |
Key Impacts of the Litigation
- For Purdue: Reinforces patent protection strategies for high-value opioid formulations.
- For Accord: Highlights the risks of patent litigation delaying market entry.
- For Industry: Demonstrates ongoing patent disputes as a barrier to generic competition.
- For Public Health: Courts balancing patent rights with public interest remains central.
Key Takeaways
- Purdue is actively defending its patent rights against Accord’s generic OxyContin.
- The case exemplifies common patent tactics in the pharma industry—assertions of validity, infringement, and potential challenges.
- The outcome could influence the timing of generic market entry, affecting drug prices and availability.
- Litigation emphasizes the importance of robust patent prosecution and defense strategies.
- Public health considerations are increasingly influencing legal outcomes, especially with opioids.
FAQs
Q1: What patents is Purdue Pharma asserting in this case?
A1: Purdue advocates claims covering controlled-release formulations and delivery mechanisms for oxycodone, with specific patent numbers and claims aimed at extending market exclusivity ([2]).
Q2: How does Accord Healthcare defend against patent infringement claims?
A2: Accord argues its generic formulations differ sufficiently and that Purdue’s patents are invalid due to prior art or obviousness, seeking to invalidate Purdue’s patent rights.
Q3: What are the typical durations for cases like this?
A3: Patent litigation involving pharmaceuticals generally lasts 1-3 years, with proceedings such as IPRs, motions, and potential settlement negotiations.
Q4: Could this case influence the availability of generic opioids?
A4: Yes. A ruling favoring Purdue could delay generic entry, maintaining high prices, whereas invalidation of patents could expedite access.
Q5: How have courts balanced patent rights against public health in opioid litigation?
A5: Courts weigh patent protections against public health risks, sometimes issuing preliminary injunctions or considering public interest factors during litigation.
References
- [1] U.S. District Court, District of Delaware. Case 1:22-cv-00913. "Purdue Pharma L.P. v. Accord Healthcare Inc."
- [2] USPTO Patent Database. Patent filings and granted patents related to Purdue’s opioid formulations.
- [3] Public health reports on opioid market dynamics and litigation impacts (e.g., CDC opioid guidelines).
In conclusion, the Purdue Pharma v. Accord Healthcare case underscores the delicate balance between patent enforcement and market competition in a high-stakes, public health-sensitive environment. Strategic legal positioning and regulatory policies will shape the case outcome and industry evolution.
